SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    US Department of Health and Human Services, Office of Inspector General. Appropriateness of Medicare prescription drug allowances. Washington (DC): HHS; 1996.
  • 2
    US Department of Health and Human Services, Office of Inspector General. Appropriateness of Medicare prescription drug allowances. Washington (DC): HHS; 1997.
  • 3
    US Department of Health and Human Services, Office of Inspector General. Medicare reimbursement of prescription drugs. Washington (DC): HHS; 2001.
  • 4
    US General Accounting Office. Report to Congressional Committees. Medicare: payments for covered outpatient drugs exceed providers' cost. Washington (DC): GAO; 2001.
  • 5
    Danzon PM, Wilensky GR, Means KE. Alternative strategies for Medicare payment of outpatient prescription drugs: part B and beyond. Am J Manag Care 2005; 11: 17380.
  • 6
    Federal Register: rules and regulations. Vol. 69, no. 219. 2004. URL: http://www.edocket.access.gpo.gov/2004/pdf/04-24758.pdf.
  • 7
    Medicare Payment Advisory Commission. Report to the congress: variation and innovation in Medicare. June 2003. URL: http://www.medpac.gov/documents/June03_Entire_Report.pdf.
  • 8
    Gabel JR, Rice TH. Reducing public expenditures for physician services: the price of paying less. J Health Polit Policy Law 1985; 9: 595609.
  • 9
    McGuire TG, Pauly MV. Physician response to fee changes with multiple payers. J Health Econ 1991; 10: 385410.
  • 10
    Yip WC. Physician response to Medicare fee reductions: changes in the volume of coronary artery bypass graft (CABG) surgeries in the Medicare and private sectors. J Health Econ 1998; 17: 67599.
  • 11
    Medicare Payment Advisory Commission. Effect of Medicare payment changes on oncology services. 2006. URL: http://www.medpac.gov/documents/Jan07_PartB_mandated_report.pdf.
  • 12
    Medicare Payment Advisory Commission. Report to the congress: impact of changes in Medicare payments for part B drugs. 2007. URL: http://www.medpac.gov/documents/Jan07_partb_mandated_report.pdf.
  • 13
    Christensen S. Volume response to exogenous changes in Medicare's payment policies. Health Serv Res 1992; 27: 6579.
  • 14
    Centers for Medicare/Medicaid Services (CMS), Health and Human Services. Physician volume and intensity response. Baltimore (MD): CMS; 1998.
  • 15
    Rice TH. The impact of changing Medicare reimbursement rates on physician-induced demand. Med Care 1983; 21: 80315.
  • 16
    Rice T. Physician-induced demand for medical care: new evidence from the Medicare program. Adv Health Econ Health Serv Res 1984; 5: 12960.
  • 17
    Rice TH, Labelle RJ. Do physicians induce demand for medical services? J Health Polit Policy Law 1989; 14: 587600.
  • 18
    Wedig G, Mitchell JB, Cromwell J. Can price controls induce optimal physician behavior? J Health Polit Policy Law 1989; 14: 60120.
  • 19
    Research Data Assistance Center. Medicare data file descriptions. 2009. URL: http://www.resdac.umn.edu/Medicare/data_file_descriptions.asp#rif.
  • 20
    Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis Rheum 2008; 58: 93946.
  • 21
    Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148: 12434.
  • 22
    Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas B, et al. Comparative effectiveness of drug therapy for rheumatoid arthritis and psoriatic arthritis in adults. Rockville (MD): Agency for Healthcare Research and Quality; 2007.
  • 23
    Fraenkel L, Bogardus S, Concato J, Felson D, Wittink D. Patient preferences for treatment of rheumatoid arthritis. Br Med J 2004; 63: 13728.
  • 24
    Jarry JL, Coambs RB, De Maio FG, Rattray AH, Balaram R, Russell A. Projected patterns of compliance associated with remicade (infliximab) and enbrel (etarcept). J Rheumatol 2002; 29: 1568. [abstract].
  • 25
    DeWitt EM, Glick HA, Albert DA, Joffe MM, Wolfe F. Medicare coverage of tumor necrosis factor α inhibitors as an influence on physicians' prescribing behavior. Arch Intern Med 2006; 166: 5763.
  • 26
    Singh JA, Holmgren AR, Noorbaloochi S. Accuracy of Veterans Administration databases for a diagnosis of rheumatoid arthritis. Arthritis Rheum 2004; 51: 9527.